{"doc_id": "si-2022-0414-reg-1", "parent_doc_id": "si-2022-0414", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 414 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "1. (1) These Regulations may be cited as the Medicinal Products (Control", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products (Control \n\nof Manufacture) (Amendment) (No. 2) Regulations 2022. \n\n(2) The Principal Regulations, \n\nthe Medicinal Products (Control of \nManufacture) (Amendment) Regulations 2009 (S.I. No. 4 of 2009), the \nMedicinal Products (Control of Manufacture) (Amendment) Regulations 2010 \n(S.I. No. 288 of 2010), the Medicinal Products (Control of Manufacture) \n(Amendment) Regulations 2012 (S.I. No. 273 of 2012), the Medicinal Products \n(Control of Manufacture) (Amendment) Regulations 2013 (S.I. No. 163 of \n2013), Regulation 8 of the Medicinal Products (Safety Features on Packaging) \nRegulations 2019 (S.I. No. 36 of 2019), the Medicinal Products (Control of \nManufacture) (Amendment) Regulations 2019 (S.I. No. 219 of 2019), the \nMedicinal Products (Control of Manufacture) (Amendment) Regulations 2022 \n(S.I. No. 43 of 2022) and these Regulations may be cited together as “the \nMedicinal Products (Control of Manufacture) Regulations 2007 to 2022”.", "text_norm": "1 (1) regulation may cited medicinal product (control manufacture) (amendment) (no 2) regulation 2022 (2) principal regulation medicinal product (control manufacture) (amendment) regulation 2009 (s.i no 4 2009) medicinal product (control manufacture) (amendment) regulation 2010 (s.i no 288 2010) medicinal product (control manufacture) (amendment) regulation 2012 (s.i no 273 2012) medicinal product (control manufacture) (amendment) regulation 2013 (s.i no 163 2013) regulation 8 medicinal product (safety feature packaging) regulation 2019 (s.i no 36 2019) medicinal product (control manufacture) (amendment) regulation 2019 (s.i no 219 2019) medicinal product (control manufacture) (amendment) regulation 2022 (s.i no 43 2022) regulation may cited together medicinal product (control manufacture) regulation 2007 2022", "start_char": 739, "end_char": 1751, "source_path": "downloads\\2022\\2022_0413.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f15fc2234b5caad43b9b104264a21473a14e03f0fc23e79a9ab54987eeb1ea07", "cross_refs": []}
{"doc_id": "si-2022-0414-reg-2", "parent_doc_id": "si-2022-0414", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 414 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "2. These Regulations shall be deemed to have come into operation on 1", "text_raw": "2. These Regulations shall be deemed to have come into operation on 1 \n\nJanuary 2022.", "text_norm": "2 regulation shall deemed come operation 1 january 2022", "start_char": 1751, "end_char": 1839, "source_path": "downloads\\2022\\2022_0413.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f15fc2234b5caad43b9b104264a21473a14e03f0fc23e79a9ab54987eeb1ea07", "cross_refs": []}
{"doc_id": "si-2022-0414-reg-3", "parent_doc_id": "si-2022-0414", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 414 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "In these Regulations “Principal Regulations” means the Medicinal", "text_raw": "3. \n\nIn these Regulations “Principal Regulations” means the Medicinal \n\nProducts (Control of Manufacture) Regulations 2007 (S.I. No. 539 of 2007).", "text_norm": "3 regulation principal regulation mean medicinal product (control manufacture) regulation 2007 (s.i no 539 2007)", "start_char": 1839, "end_char": 1988, "source_path": "downloads\\2022\\2022_0413.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f15fc2234b5caad43b9b104264a21473a14e03f0fc23e79a9ab54987eeb1ea07", "cross_refs": []}
{"doc_id": "si-2022-0414-reg-4", "parent_doc_id": "si-2022-0414", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 414 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "4. Regulation 3(1) of the Principal Regulations is amended –", "text_raw": "4. Regulation 3(1) of the Principal Regulations is amended – \n\n(a) by substituting for the definition of “2001 Directive” the \n\nfollowing: \n“‘2001 Directive’ means Directive 2001/83/EC of the European \nParliament and of the Council on the Community code relating \nto medicinal products for human use3 (as amended);”, \n(b) by substituting for the definition of “export” the following: \n\n“‘export’ means exportation to a third country, other than \nNorthern Ireland;”, and \n\n(c) by substituting for the definition of “import” the following: \n\n1 OJ No. L. 118, 20.4.2022, p.4. \n3 OJ No. L. 311, 28.11.2001, p.67. \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 23rd August, 2022. \n\n \n \n \n \n \n \n \n \n \n\f“‘import’ means importation from a third country, other than \nNorthern Ireland;”. \n\n[414] 3", "text_norm": "4 regulation 3(1) principal regulation amended - (a) substituting definition 2001 directive following 2001 directive mean directive 2001 83 ec european parliament council community code relating medicinal product human use3 (as amended) (b) substituting definition export following export mean exportation third country northern ireland (c) substituting definition import following 1 oj no l 118 20.4.2022 p.4 3 oj no l 311 28.11.2001 p.67 notice making statutory instrument published iris oifigiuil 23rd august 2022 import mean importation third country northern ireland  414 3", "start_char": 1988, "end_char": 2821, "source_path": "downloads\\2022\\2022_0413.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f15fc2234b5caad43b9b104264a21473a14e03f0fc23e79a9ab54987eeb1ea07", "cross_refs": []}
{"doc_id": "si-2022-0414-reg-5", "parent_doc_id": "si-2022-0414", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 414 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "5. Regulation 4(a) of the Principal Regulations is amended by inserting", "text_raw": "5. Regulation 4(a) of the Principal Regulations is amended by inserting \n\n“or in Northern Ireland” after “EEA”.", "text_norm": "5 regulation 4(a) principal regulation amended inserting northern ireland eea", "start_char": 2821, "end_char": 2935, "source_path": "downloads\\2022\\2022_0413.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f15fc2234b5caad43b9b104264a21473a14e03f0fc23e79a9ab54987eeb1ea07", "cross_refs": []}
{"doc_id": "si-2022-0414-reg-6", "parent_doc_id": "si-2022-0414", "section_id": "reg-6", "section_label": "Regulation 6.", "si_number": "S.I. No. 414 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "6. Regulation 5 of the Principal Regulations is amended –", "text_raw": "6. Regulation 5 of the Principal Regulations is amended – \n\n(a) by inserting after subparagraph 5(1)(f) the following: \n\n“(g) until 31 December 2024, the import of medicinal products \nfrom parts of the United Kingdom other than Northern Ireland \nby holders of a wholesaler’s authorisation that are not in \npossession of a relevant manufacturing authorisation, which \nshall be allowed by the Board following receipt of a request \nfrom the holders of the marketing authorisations for the \nmedicinal products, where all of the following conditions are \nfulfilled – \n\n(i) \n\n(ii) \n\n(iii) \n\n(iv) \n\n(v) \n\nthe medicinal products have undergone quality control \ntesting either in the Union, as provided for in Article 51(3) \nof the 2001 Directive, or in parts of the United Kingdom \nother than Northern Ireland in compliance with Article 20, \nfirst paragraph, point (b) of the 2001 Directive, \n\nthe medicinal products have been subject to batch release \nby a qualified person in the Union in accordance with \nArticle 51(1) of the 2001 Directive, or in parts of the \nUnited Kingdom other than Northern Ireland applying \nquality standards that are equivalent to those laid down in \nArticle 51(1) of the 2001 Directive, \n\nthe marketing authorisation for the medicinal product \nconcerned has been granted in accordance with relevant \nCommunity provisions, by the Health Products Regulatory \nAuthority or by the Commission, \n\nthe medicinal products are only made available to patients \nor end-consumers in the State, and \n\nthe medicinal products bear the safety features referred to \nin Article 54, point (o) of the 2001 Directive.”, and \n\n(b) by inserting after subparagraph 5(3) the following: \n\n“(4) until 31 December 2024, Article 80, first subparagraph, \npoint (b) of the 2001 Directive shall not apply to imports that \nfulfil the conditions laid down in sub-paragraph 5(1)(g).”.", "text_norm": "6 regulation 5 principal regulation amended - (a) inserting subparagraph 5(1)(f) following (g) 31 december 2024 import medicinal product part united kingdom northern ireland holder wholesaler authorisation possession relevant manufacturing authorisation shall allowed board following receipt request holder marketing authorisation medicinal product following condition fulfilled - (i) (ii) (iii) (iv) (v) medicinal product undergone quality control testing either union provided article 51(3) 2001 directive part united kingdom northern ireland compliance article 20 first paragraph point (b) 2001 directive medicinal product subject batch release qualified person union accordance article 51(1) 2001 directive part united kingdom northern ireland applying quality standard equivalent laid article 51(1) 2001 directive marketing authorisation medicinal product concerned granted accordance relevant community provision health product regulatory authority commission medicinal product made available patient end-consumers state medicinal product bear safety feature referred article 54 point (o) 2001 directive (b) inserting subparagraph 5(3) following (4) 31 december 2024 article 80 first subparagraph point (b) 2001 directive shall apply import fulfil condition laid sub-paragraph 5(1)(g)", "start_char": 2935, "end_char": 4808, "source_path": "downloads\\2022\\2022_0413.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f15fc2234b5caad43b9b104264a21473a14e03f0fc23e79a9ab54987eeb1ea07", "cross_refs": []}
{"doc_id": "si-2022-0414-reg-7", "parent_doc_id": "si-2022-0414", "section_id": "reg-7", "section_label": "Regulation 7.", "si_number": "S.I. No. 414 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "7. Regulation 13 of the Principal Regulations is amended –", "text_raw": "7. Regulation 13 of the Principal Regulations is amended – \n\n(a) \n\nin Regulation 13(3), by the substitution of “Without prejudice to \nRegulations 13(9) and 13(10), the functions of a qualified \nperson shall be -” for “The functions of the qualified person \nshall be -”, \n\n \n \n \n \n\f4 [414] \n\n(b) \n\nin Regulation 13(4): \n\n(i) \n\nby the substitution of “Without prejudice to Regulations \n13(9) and 13(10), the batches” for “The batches”, and \n\n(ii) by the insertion of “or Northern Ireland” after “in another \n\nEEA State”, \n\n(c) \n\nin Regulation 13(5), by the substitution of “Without prejudice to \nRegulations 13(9) and 13(10), in the case of medicinal products” \nfor “In the case of medicinal products”, \n\n(d) by inserting after subparagraph (8) the following: \n\n“(9) Until 31 December 2024, with regard to quality control \ntesting carried out in parts of the United Kingdom other than \nNorthern Ireland regarding medicinal products included in the \nlist referred to in Article 127d of the 2001 Directive other than \nthose authorised by the Commission, the Board may consider \nthat there is a justifiable case within the meaning of point (b) of \nthe first paragraph of Article 20 of the 2001 Directive, without \ncarrying out a case-by-case assessment provided that – \n\n(a) \n\neach batch of the medicinal products concerned is released \nby a qualified person on a site in the Union or in Northern \nIreland or by a qualified person on a site in parts of the \nUnited Kingdom other than Northern Ireland applying \nquality standards that are equivalent to those laid down in \nArticle 51 of the 2001 Directive, \n\n(b) \n\nthe establishment designated by the third party conducting \nthe quality control testing is supervised by the competent \nauthority of the United Kingdom, including by performing \non-the-spot checks, and \n\n(c) where the batch release is carried out by a qualified person \n\nwho operates in parts of the United Kingdom other than \nNorthern Ireland, the manufacturing authorisation holder \ndeclares that it does not have at its disposal a qualified \nperson who resides and operates in the Union on 20 April", "text_norm": "7 regulation 13 principal regulation amended - (a) regulation 13(3) substitution without prejudice regulation 13(9) 13(10) function qualified person shall - function qualified person shall - 4 414 (b) regulation 13(4) (i) substitution without prejudice regulation 13(9) 13(10) batch batch (ii) insertion northern ireland another eea state (c) regulation 13(5) substitution without prejudice regulation 13(9) 13(10) case medicinal product case medicinal product (d) inserting subparagraph (8) following (9) 31 december 2024 regard quality control testing carried part united kingdom northern ireland regarding medicinal product included list referred article 127d 2001 directive authorised commission board may consider justifiable case within meaning point (b) first paragraph article 20 2001 directive without carrying case-by-case assessment provided - (a) batch medicinal product concerned released qualified person site union northern ireland qualified person site part united kingdom northern ireland applying quality standard equivalent laid article 51 2001 directive (b) establishment designated third party conducting quality control testing supervised competent authority united kingdom including performing on-the-spot check (c) batch release carried qualified person operates part united kingdom northern ireland manufacturing authorisation holder declares disposal qualified person resides operates union 20 april", "start_char": 4808, "end_char": 6920, "source_path": "downloads\\2022\\2022_0413.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f15fc2234b5caad43b9b104264a21473a14e03f0fc23e79a9ab54987eeb1ea07", "cross_refs": []}
{"doc_id": "si-2022-0414-reg-2022", "parent_doc_id": "si-2022-0414", "section_id": "reg-2022", "section_label": "Regulation 2022.", "si_number": "S.I. No. 414 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "2022.”, and", "text_raw": "2022.”, and \n\n(e) by inserting after subparagraph (9) the following: \n\ninto \n\nimported \n\nthe State, \n\n“(10) Until 31 December 2024, for batches of medicinal \nproducts which are exported to parts of the United Kingdom \nother \nthan Northern Ireland from a Member State and \nthe controls upon \nsubsequently \nimportation referred to in the first and second subparagraphs of \nArticle 51(1) of the 2001 Directive shall not be required, \nprovided that those batches have undergone such controls in a \nMember State prior to being exported to parts of the United \nKingdom other than Northern Ireland and that they are \naccompanied by the control reports referred to in the third \nsubparagraph of Article 51(1) of the 2001 Directive.” \n\n \n \n\f[414] 5", "text_norm": "2022 (e) inserting subparagraph (9) following imported state (10) 31 december 2024 batch medicinal product exported part united kingdom northern ireland member state control upon subsequently importation referred first second subparagraphs article 51(1) 2001 directive shall required provided batch undergone control member state prior exported part united kingdom northern ireland accompanied control report referred third subparagraph article 51(1) 2001 directive 414 5", "start_char": 6920, "end_char": 7662, "source_path": "downloads\\2022\\2022_0413.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f15fc2234b5caad43b9b104264a21473a14e03f0fc23e79a9ab54987eeb1ea07", "cross_refs": []}
{"doc_id": "si-2022-0414-reg-8", "parent_doc_id": "si-2022-0414", "section_id": "reg-8", "section_label": "Regulation 8.", "si_number": "S.I. No. 414 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "8. The Principal Regulations are amended by inserting after Regulation 16", "text_raw": "8. The Principal Regulations are amended by inserting after Regulation 16 \n\nthe following: \n\n“17. (1) By 20 May 2022, the Board shall establish, notify to the Commission \nand publish on its website a list of medicinal products to which it has applied \nor intends to apply the derogations as set out in Regulations 5(1)(g), 13(9) and \n13(10) of these Regulations. \n\n(2) The Board shall ensure that the list referred to in paragraph (1) is \n\nupdated at least on a six-monthly basis. \n\n(3) Any marketing authorisation holder who intends to avail of the \nderogations set out in Regulations 5(1)(g), 13(9) and 13(10) of these \nRegulations shall notify the Board and ensure that the relevant medicinal \nproduct is included on the list referred to in paragraph (1) before the relevant \nmedicinal product is placed on the market in the State. Manufacturers and \nimporters shall not apply those derogations with respect to any medicinal \nproduct until the relevant medicinal product is included on the list referred to in \nparagraph (1).” \n\nGIVEN under the Official Seal of the Minister for Health, \n\n18 August, 2022. \n\nMUIRIS O'CONNOR, \n\nA person authorised under section 15 of the Ministers and \nSecretaries Act 1924 to authenticate the seal of the \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n\f6 [414]", "text_norm": "8 principal regulation amended inserting regulation 16 following 17 (1) 20 may 2022 board shall establish notify commission publish website list medicinal product applied intends apply derogation set regulation 5(1)(g) 13(9) 13(10) regulation (2) board shall ensure list referred paragraph (1) updated least six-monthly basis (3) marketing authorisation holder intends avail derogation set regulation 5(1)(g) 13(9) 13(10) regulation shall notify board ensure relevant medicinal product included list referred paragraph (1) relevant medicinal product placed market state manufacturer importer shall apply derogation respect medicinal product relevant medicinal product included list referred paragraph (1) given official seal minister health 18 august 2022 muiris connor person authorised section 15 minister secretary act 1924 authenticate seal minister health 6 414", "start_char": 7662, "end_char": 8957, "source_path": "downloads\\2022\\2022_0413.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f15fc2234b5caad43b9b104264a21473a14e03f0fc23e79a9ab54987eeb1ea07", "cross_refs": []}
{"doc_id": "si-2022-0414-explanatory-note", "parent_doc_id": "si-2022-0414", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 414 of 2022", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2022, "heading": "(This note is not part of the instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the instrument and does not purport to be a legal \ninterpretation) \n\nThe main purpose of these Regulations is to implement Articles 2(4), 2(5) and \n2(11) of Directive (EU) 2022/642 of the European Parliament and of the \nCouncil of 12 April 2022, which amend Directive 2001/83/EC as regards \nderogations from certain obligations concerning certain medicinal products for \nhuman use. \n\n \n \n \n \n \n \n\f[414] 7 \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.00 \n\n(DH-436) 75. 8/22. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation) main purpose regulation implement article 2(4) 2(5) 2(11) directive (eu) 2022 642 european parliament council 12 april 2022 amend directive 2001 83 ec regard derogation certain obligation concerning certain medicinal product human use 414 7 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.00 (dh-436) 75 8 22 propylon", "start_char": 8957, "end_char": 9892, "source_path": "downloads\\2022\\2022_0413.pdf", "extraction_method": "pdfminer", "checksum": "sha256:f15fc2234b5caad43b9b104264a21473a14e03f0fc23e79a9ab54987eeb1ea07", "cross_refs": []}
